129 related articles for article (PubMed ID: 7089337)
61. Clinical images: Skeletal muscle pseudo-hypertrophy in myeloma-associated amyloidosis.
Lawson TM; Bevan MA; Williams BD
Arthritis Rheum; 2002 Aug; 46(8):2251. PubMed ID: 12209535
[No Abstract] [Full Text] [Related]
62. Use of recombinant erythropoietin in the treatment of anaemia associated with multiple myeloma in a haemodialysis patient.
Hussein MM; Mooij JM; Roujouleh H
Nephrol Dial Transplant; 1994; 9(7):876-7. PubMed ID: 7818713
[No Abstract] [Full Text] [Related]
63. Renal failure in multiple myeloma.
Sabljar-Matovinović M; Tićak M; Skegro D; Juricić D; Preden V
Przegl Lek; 1985; 42(4):381-3. PubMed ID: 4048524
[No Abstract] [Full Text] [Related]
64. [Current prognosis of multiple myeloma with renal failure].
Hemery M; Dueymes JM; Vernier I; Thierry FX; Pourrat JP; Conté JJ
Ann Med Interne (Paris); 1987; 138(5):379. PubMed ID: 3674615
[No Abstract] [Full Text] [Related]
65. [Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].
Martín Reyes G; García González I; Alférez MJ; Martínez González JM; Frutos MA
Nefrologia; 2001; 21(2):213-6. PubMed ID: 11464657
[TBL] [Abstract][Full Text] [Related]
66. My most interesting cases.
Kawai T; Sachs DH; Sykes M; Spitzer T; Tolkoff-Rubin N; Saidman S; Ko D; Dey B; Colvin RB; Cosimi AB
Clin Transpl; 2006; ():580-2. PubMed ID: 18365443
[No Abstract] [Full Text] [Related]
67. [Two cases of multiple myeloma with the successful endoprosthesis of the femoral head showed a satisfactory response to AAAP-therapy for relapse with extramedullary myeloma (author's transl)].
Maruo K; Yoshikawa H; Kuboyama K; Yokoe K; Shido T
Rinsho Ketsueki; 1980 Feb; 21(2):220-32. PubMed ID: 7411867
[No Abstract] [Full Text] [Related]
68. Crystalloid deposits in the kidney.
Keller LS; Faull RJ; Smith P; Swift J; Bannister KM; Otto S; Peh CA
Nephrology (Carlton); 2005 Feb; 10(1):81-3. PubMed ID: 15705186
[TBL] [Abstract][Full Text] [Related]
69. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
Terpos E
Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
[No Abstract] [Full Text] [Related]
70. Development of chronic renal failure in patients with multiple myeloma.
Iványi B
Arch Pathol Lab Med; 1993 Aug; 117(8):837-40. PubMed ID: 8343049
[TBL] [Abstract][Full Text] [Related]
71. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
72. Renal lesions in multiple myeloma.
Bosnić D; Kovacević J; Cvoriscec D
Przegl Lek; 1985; 42(4):378-80. PubMed ID: 4048523
[No Abstract] [Full Text] [Related]
73. [Clinico-pathologic conference: anemia and kidney insufficiency in a 70-year-old female patient].
Blumberg A; Huser HJ; Zimmerli B; Schmid A; Cottier H; Hodler J
Schweiz Med Wochenschr; 1982 Sep; 112(39):1353-60. PubMed ID: 6815797
[No Abstract] [Full Text] [Related]
74. The efficacy and safety of bortezomib (velcade) in the treatment of relapsed multiple mye.
Warzocha K; Kraj M; Pogłód R; Sokołowska U
Acta Pol Pharm; 2006; 63(5):452-5. PubMed ID: 17357614
[No Abstract] [Full Text] [Related]
75. Plasmapheresis and hemodialysis in the treatment of acute renal failure in multiple myeloma.
Kes P; Pecanić Z; Getaldić B
Acta Med Croatica; 1995; 49(1):39-42. PubMed ID: 7633177
[TBL] [Abstract][Full Text] [Related]
76. [Treatment of a hypercalcemic crisis in a myelomatous patient under chronic hemodialysis. The role of calcitonin].
Bissoli F; Simonati V; Volpini T; Novi C
Minerva Nefrol; 1980; 27(2):351-4. PubMed ID: 7219856
[No Abstract] [Full Text] [Related]
77. [IgM multiple myeloma. Case report and review of the literature [].
Marín-López A; Landero de Ruiz N; Armenta Olvera T; Ruiz-Argüelles GJ
Rev Invest Clin; 1982; 34(2):175-8. PubMed ID: 7123028
[No Abstract] [Full Text] [Related]
78. [Primary treatment results in myeloma disease using a cytostatic preparation].
Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
[No Abstract] [Full Text] [Related]
79. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
80. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency.
Ballester OF; Tummala R; Janssen WE; Fields KK; Hiemenz JW; Goldstein SC; Perkins JB; Sullivan DM; Rosen R; Sackstein R; Zorsky P; Saez R; Elfenbein GJ
Bone Marrow Transplant; 1997 Oct; 20(8):653-6. PubMed ID: 9383228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
